Meet our
Leadership Team
Our Leadership Team

Together, we have over 50 years of experience in the medical device world, and we’ve developed a number of technologies that are already impacting people’s lives—including the Watchman cardiology device invented by our Chief Medical Officer, Dr. Robert Schwartz and purchased by Boston Scientific in 2011, and the Resonic cellulite treatment launched by our CEO, CFO and Executive Chairman and purchased by AbbVie in 2021.

We were formed when co-founders, Landy Toth and Dr. Robert Schwartz, combined their knowledge and expertise with one goal in mind: to establish greater visibility into the nervous system to provide safer, more accurate treatment.

Lori Bisson

Chief Executive Officer and Director

Ms. Bisson is a seasoned Life Sciences and MedTech executive with a proven track record. She has executed multiple successful IPOs and exits, including her previous role as Chief Financial Officer of Soliton, which was acquired by AbbVie in 2021 for approximately $550 Million. Ms. Bisson joined Autonomix Medical in July 2023 as Chief Executive Officer and Director. From January 2015 until June 2022, Ms. Bisson served as Chief Financial Officer of Soliton, Inc., a medical device company focused on developing new technology for use in aesthetics.

Prior to joining Soliton, Ms. Bisson worked as a financial and business development consultant as a shareholder in Condon & Company, PC, from 2009 through December 2014, where she advised a number of life science companies. From 2005 to 2009, Ms. Bisson served as the Chief Financial Officer and Vice President of Operations for Zeno Corporation, a medical device company focused on new technology in the aesthetics area. Ms. Bisson previously served as the Chief Financial Officer of Gulfstream Trading, Ltd., an international oil trading organization, from 2001 to 2005. From 1995 to 2001, Ms. Bisson held various positions with Drypers Corporation, a publicly traded multinational consumer products company, where she ultimately held the title of Vice President of Integrated Solutions and oversaw accounting, information technology and logistics for the U.S. operation.

Ms. Bisson began her career at Arthur Andersen, LLP as an auditor focused on consumer products companies. Ms. Bisson also serves as an advisor to Moleculin Biotech, Inc., a clinical stage pharmaceutical company focused on the development of oncology drug candidates. Ms. Bisson is a Certified Public Accountant and holds a B.A. degree in Accounting from Baylor University.

Walter V. Klemp

Executive Chairman

Mr. Klemp is a serial entrepreneur with multiple successful exits through his career. Most recently, he was Chief Executive Officer of Soliton, Inc., a medical device company he co-founded, took public on Nasdaq in 2018 and which was acquired by AbbVie in 2021 for approximately $550 Million. Mr. Klemp joined Autonomix in January 2022 as Executive Chairman.

Additionally, Mr. Klemp is a Co-Founder of Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, and has served as its Chairman of the Board and Chief Executive Officer since July 2015 and as President since August 2017. From November 2011 to December 2020, Mr. Klemp served as Chief Executive Officer and then Executive Chairman on the Board of Directors of Soliton. Prior to Soliton, Mr. Klemp served as President and Chief Executive Officer of Zeno Corporation from 2004 to April 2011, where he developed and marketed dermatology devices and drugs from concept through FDA approval and market launch.

Additionally, from 1987 to 2000, Mr. Klemp served as Chief Executive Officer and Chairman of Drypers Corporation, a publicly traded multinational consumer products company that was listed as #1 on the INC 500 List of America’s Fastest Growing Companies.

Dr. Robert Schwartz

Chief Medical Officer

Dr. Schwartz is a serial medical device inventor and developer of the Watchman™, a left atrial appendage closure device and proven one-time procedure that reduces the risk of stroke in non-valvular atrial fibrillation (NVAF) patients and the risk of bleeding that comes with a long-term oral anticoagulant use. The Watchman™ sold to Boston Scientific and has generated over $1 Billion in revenue.

Dr. Schwartz is a Co-Founder of Autonomix Medical and has served as Chief Medical Officer since June 2023, and served as Chief Executive Officer from February 2022 until June 2023. In addition to his role at Autonomix, Dr. Schwartz serves as President of the Jon DeHaan Center for Medical Innovation and was previously Director at the Center for Applied Vascular Biology and Interventions, Mayo Foundation. Dr. Schwartz has also served as Professor and Associate Professor at the Mayo Medical School. He holds Board Certifications on the National Board of Medical Examiners, American Board of Internal Medicine and the American Board of Internal Medicine, Cardiovascular Diseases, is a member of the Society of Atherosclerosis Imaging and holds professional memberships as Fellow of the American College of Cardiology, American Heart Association and The Society for Cardiac Angiography and Interventions. He is the recipient of various awards including the Andreas Gruentzig Award for Basic Research in Coronary Restenosis from the Thoraxcenter/European Society of Cardiology and over the course of his career, he has published numerous articles in peer review journals dealing with various topics in interventional cardiology.

Dr. Schwartz holds a Master’s Degree in Electrical Engineering, and his doctorate from the University of Colorado-Denver and continued his internship, residency, and Fellowship at the Mayo Graduate School of Medicine.

Landy Toth

Chief Technology Officer

Mr. Toth is a mechanical engineer and medical device expert having developed and commercialized multiple wearable and interventional diagnostic medical technologies. He is a key inventor and is responsible for Autonomix’s development efforts to date.

Mr. Toth co-founded Autonomix in August 2014 and has served as Chief Technology Officer since that time. In addition to these efforts, he founded Tricord Holdings, LLC in 2012 and founded and served as Chief Technology Officer of LifeLens Technologies, Inc. since September 2016.

Mr. Toth has also been an employee of Davos Chemical Corporation since January 2011. Over the past 20 years, Mr. Toth has successfully commercialized medical device technologies within startup environments. His focus has been the development and commercialization of wearable and interventional diagnostic medical technologies. He has authored over 600 publications across 56 patent families and his portfolio has a grant rate greater than 70% after 2 years. Mr. Toth holds a MASc from the University of Toronto and a BASc from the University of Waterloo.

Trent Smith

Chief Financial Officer

Mr. Smith is a seasoned Life Sciences and MedTech financial executive with extensive experience providing financial and business leadership to private and public companies. Mr. Smith joined Autonomix Medical in July 2023 as Chief Financial Officer. Prior to joining Autonomix, from June 2018 to September 2022, Mr. Smith served as the Corporate Controller and Vice-President of Soliton, Inc., a medical device company focused on developing new technology for use in aesthetics that was acquired by AbbVie, Inc. in December 2021 for approximately $550 Million.

From 2011 to 2018, Mr. Smith held various positions with InfuSystem Holdings, Inc., a national provider of infusion pumps and related services to the healthcare industry, where he served as Corporate Controller and Vice-President before a promotion to Chief Accounting Officer and Executive Vice President. From 2010 to 2011, Mr. Smith served as the Director of External Reporting of Syncreon Holdings, Inc., an international leader in global supply chain management. From 2006 to 2010, Mr. Smith served as the Director of Accounting and Financial Reporting of Champion Homes, Inc., a leader in the manufactured housing industry and one of the largest modular homebuilders in North America. From 2005 to 2006, Mr. Smith served as the Director of External Financial Reporting for Dura Automotive Systems, a Tier 1 international designer and manufacturer of automotive components headquartered in Auburn Hills, MI.

From 1999 to 2006, Mr. Smith served in various roles and divisions for Valeo, Inc., an international Tier 1 automotive supplier, including as Financial Controller and Treasurer of Valeo Distribution North America and Director of Accounting and Internal Controls for Valeo Wiper Systems, Valoe’s largest division in North America. He began his professional career as an auditor with Deloitte & Touche, LLP in 1995. Mr. Smith served on active duty in the United States Navy from 1987 through 1991 and the reserves until 1993. Mr. Smith is a Certified Public Accountant and a graduate of the University of Illinois where he holds a Bachelor of Science in Accounting.

Stay Up-to-Date with the Future of Autonomix
Privacy Policy

Autonomix is committed to protecting your privacy. This Privacy Policy outlines our practices concerning the collection, use, and protection of your personal information when you visit our website or use our services.

1. Information We Collect

We may collect personal information that you voluntarily provide to us, including but not limited to:

  • Name
  • Email address
  • Contact information
  • Billing and payment details
  • User-generated content (e.g., comments, reviews)

We may also collect non-personal information, such as:

  • Browser type
  • IP address
  • Device information
  • Cookies and usage data

2. How We Use Your Information

We may use your personal information for various purposes, including but not limited to:

  • Providing, maintaining, and improving our website and services.
  • Processing transactions and payments.
  • Sending updates, newsletters, and promotional materials.
  • Responding to your inquiries and requests.
  • Complying with legal obligations.


3. Cookies and Tracking Technologies

We use cookies and similar tracking technologies to collect information about your browsing behavior on our website. You can manage your cookie preferences through your browser settings.

4. Disclosure of Your Information

We may share your personal information with third parties under the following circumstances:

  • With your consent.
  • To comply with legal obligations.
  • To protect our rights, privacy, safety, or property.
  • In connection with the sale, merger, or acquisition of all or part of our business.

5. Your Rights

You have the right to:

  • Access, update, or delete your personal information.
  • Object to the processing of your personal information.
  • Withdraw your consent, where applicable.
  • Lodge a complaint with a supervisory authority.

6. Data Security

We take reasonable measures to protect your personal information from unauthorized access, disclosure, alteration, or destruction. However, no method of data transmission over the internet or electronic storage is entirely secure. Therefore, we cannot guarantee its absolute security.

7. Children’s Privacy

Our website and services are not intended for children under the age of 13. We do not knowingly collect personal information from children. If you believe that a child has provided us with their personal information, please contact us, and we will take appropriate steps to delete the information.

8. Changes to this Privacy Policy

We may update this Privacy Policy from time to time to reflect changes in our practices or for other operational, legal, or regulatory reasons. We encourage you to review this Privacy Policy periodically for any updates.

9. Contact Us

If you have any questions or concerns about this Privacy Policy or our data practices, please contact us at autonomix@jtcir.com.

Terms & Conditions

1. Acceptance of Terms

By accessing and using this website, you agree to abide by these Terms and Conditions, as well as any applicable laws and regulations. If you do not agree with these terms, please refrain from using this website.

2. Use of Content

All content on this website, including but not limited to text, images, graphics, videos, and logos, is the property of Autonomix or its affiliates and is protected by intellectual property laws. You may not reproduce, distribute, or display any content without prior written permission.

3. User Conduct

You agree not to engage in any of the following activities while using this website:

  • Violating any applicable laws or regulations.
  • Uploading or transmitting any content that is harmful, offensive, or infringing on the rights of others.
  • Attempting to gain unauthorized access to the website, its servers, or user data.
  • Interfering with the website’s functionality or security.

4. Privacy Policy

Your use of this website is also governed by our Privacy Policy, which outlines how we collect, use, and protect your personal information. By using this website, you consent to the practices described in our Privacy Policy.

5. Links to Third-Party Websites

This website may contain links to third-party websites. These links are provided for convenience only, and Autonomix does not endorse or assume responsibility for the content or practices of these websites. Accessing third-party websites is at your own risk.

6. Disclaimer of Warranties

This website is provided “as is,” without any warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose, or non-infringement. Autonomix does not warrant that the website will be error-free or uninterrupted.

7. Limitation of Liability

To the fullest extent permitted by law, Autonomix shall not be liable for any direct, indirect, incidental, consequential, or punitive damages arising out of or related to your use of this website. This includes but is not limited to any loss of data or profits.

8. Governing Law

These Terms and Conditions shall be governed by and construed in accordance with the laws of the United States. Any disputes arising under these terms shall be subject to the exclusive jurisdiction of the courts in the United States.

9. Changes to Terms and Conditions

Autonomix reserves the right to modify or revise these Terms and Conditions at any time. It is your responsibility to review this page periodically for updates. Your continued use of the website after any changes signifies your acceptance of the revised terms.

10. Contact Information

If you have any questions or concerns about these Terms and Conditions, please contact us at autonomix@jtcir.com.

Be The First To Get Updates About Autonomix
Skip to content